SCHEMBL20072070

SCHEMBL20072070

c1csc(N2c3ccccc3N(c3cccs3)C2C2N(c3cccs3)c3ccccc3N2c2cccs2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.33
KDM4E B2RXH2 5/20 0.33
HPGD P15428 4/20 0.33
DRD4 P21917 3/20 0.33
DRD3 P35462 2/20 0.33
CASP1 P29466 1/20 0.33
HSD17B10 Q99714 1/20 0.33
DRD2 P14416 1/20 0.33
MAPT P10636 4/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
GAA P10253 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
SMN1; SMN2 Q16637 4/20 0.32
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
GLA P06280 1/20 0.31
ATM Q13315 1/20 0.31
RCE1 Q9Y256 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20062962 0.76 TLR9 (0.34) ALDH1A1KDM4EHPGDDRD4DRD3
SCHEMBL19684256 0.67 EGLN1 (0.33)
SCHEMBL22619416 0.67 GSK3B (0.31)
SCHEMBL31314498 0.67 MAOA (0.47) ALDH1A1CASP1MAPTSMN1; SMN2NPC1
SCHEMBL2499041 0.67 MAOA (0.47) ALDH1A1CASP1MAPTSMN1; SMN2NPC1
SCHEMBL13296023 0.67 MAOA (0.42) ALDH1A1KDM4EHPGDDRD3CASP1
SCHEMBL19603637 0.67 HPGD (0.43) ALDH1A1KDM4EHPGDDRD4DRD3
SCHEMBL19603574 0.65 P2RX4 (0.39) HPGDMAPTSMN1; SMN2NPSR1TP53
SCHEMBL17364348 0.64 GAA (0.41) ALDH1A1KDM4EHPGDMAPTMEN1
SCHEMBL23707405 0.63 TSHR (0.49) ALDH1A1HPGDDRD4DRD3DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10541260-B2 Organic photoelectric conversion element, optical area sensor, imaging device, and imaging apparatus CANON KABUSHIKI KAISHA (JP) 2020-01-21 US disclosed
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same CANON KABUSHIKI KAISHA (JP) 2019-01-29 US disclosed
US-20180108691-A1 ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS CANON KABUSHIKI KAISHA (JP) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same BRD1, DRD1, NR2E3 ALDH1A1 395/4885KDM4E 3246/4885HPGD 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.